SCHEMBL10248874

SCHEMBL10248874

Cc1ccc2nc(-c3ccncc3)n(C)c2c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.66
KMT2A Q03164 2/20 0.66
ATM Q13315 1/20 0.50
CYP11B1 P15538 1/20 0.50
CYP11B2 P19099 1/20 0.50
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
AAK1 Q2M2I8 1/20 0.46
KDM4E B2RXH2 4/20 0.44
ALDH1A1 P00352 4/20 0.44
TP53 P04637 3/20 0.44
HSD17B10 Q99714 3/20 0.44
PKM P14618 2/20 0.44
GAA P10253 1/20 0.44
ALOX15 P16050 1/20 0.44
LMNA P02545 3/20 0.43
MAPT P10636 3/20 0.43
RECQL P46063 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HPGD P15428 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10249140 0.87 MEN1 (0.66) MEN1KMT2AATMNPC1RAB9A
SCHEMBL1104822 0.85 ATM (0.55) MEN1KMT2AATMCYP11B1CYP11B2
SCHEMBL10175359 0.84 MEN1 (0.62) MEN1KMT2AATMCYP11B1CYP11B2
SCHEMBL26603181 0.84 MEN1 (0.62) MEN1KMT2AATMCYP11B1CYP11B2
SCHEMBL10249413 0.81 MEN1 (0.63) MEN1KMT2AATMCYP11B1CYP11B2
SCHEMBL175367 0.80 MEN1 (0.57) MEN1KMT2AATMCYP11B1CYP11B2
SCHEMBL10249302 0.80 AAK1 (0.52) MEN1KMT2ACYP11B1CYP11B2AAK1
SCHEMBL17897060 0.80 MEN1 (0.57) MEN1KMT2AATMCYP11B1CYP11B2
SCHEMBL1104864 0.80 ALDH1A1 (0.54) MEN1KMT2AATMKDM4EALDH1A1
SCHEMBL10424045 0.80 ALDH1A1 (0.58) MEN1KMT2AATMCYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461181-B2 Fused heterocyclic compound and use thereof SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2013-06-11 US disclosed
US-8273764-B2 Fused heterocyclic compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-09-25 US disclosed
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-07-12 US disclosed
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 MEN1 637/4885KMT2A 1877/4885ATM 4476/4885
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 MEN1 637/4885KMT2A 1877/4885ATM 4476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.